Equities research analysts expect that Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) will announce earnings of ($0.57) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Biohaven Pharmaceutical Holding Co’s earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.63). The firm is scheduled to issue its next quarterly earnings report on Friday, September 15th.

On average, analysts expect that Biohaven Pharmaceutical Holding Co will report full year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($3.28) to ($3.08). For the next year, analysts expect that the business will report earnings of ($3.86) per share, with EPS estimates ranging from ($4.72) to ($3.20). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Biohaven Pharmaceutical Holding Co.

BHVN has been the topic of a number of recent research reports. Morgan Stanley initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, May 31st. They set an “overweight” rating on the stock. William Blair initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price target on the stock. Barclays PLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “overweight” rating and a $30.00 price target on the stock. Piper Jaffray Companies initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “overweight” rating and a $21.00 price target on the stock. Finally, Needham & Company LLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set a “buy” rating and a $30.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $31.75.

Shares of Biohaven Pharmaceutical Holding Co (BHVN) opened at 24.24 on Wednesday. The stock has a 50 day moving average of $25.25 and a 200-day moving average of $23.82. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $29.50. The company’s market capitalization is $866.53 million.

TRADEMARK VIOLATION NOTICE: “” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.com-unik.info/2017/08/19/775318-updated.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Biohaven Pharmaceutical Holding Co Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biohaven Pharmaceutical Holding Co Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit